Stay updated with breaking news from Schering Corp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Where an alleged infringer administers a substance A to a subject, and the substance is subsequently transformed to a therapeutic agent X inside the subject’s body, does the...
Novartis is currently involved in a multi-district patent litigation campaign to block generic entrants for its blockbuster heart medication. On July 7, the district court invalidated the patent for lack of written description despite rejecting an enablement defense based upon the same evidence.
On December 9, 1941, U.S. Treasury agents raided the offices of The Schering Corporation of Bloomfield.
On November 15th, the Federal Circuit handed down its opinion affirming all aspects of the District Court's decision in Pharmacyclics LLC v. Alvogen, Inc. The case illustrates once...
New Delhi, Aug 9: Unichem Laboratories Ltd on Tuesday said it has received an approval from the US health regulator to market its generic version of labetalol hydrochloride tablets used to treat high blood pressure. The approval granted by the US Food and Drug Administration (USFDA) is for the Abbreviated New Drug Application (ANDA) of labetalol hydrochloride tablets of strengths 100 mg, 200 mg, and 300 mg, the company said in a regulatory filing. These are generic equivalent of Normodyne […]